FDA
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $560 at Truist Securities
-
-
-
-
-
-
-
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $436 at Canaccord
-
-
-
-
-
-
-
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
-
-
-
-
-
-
-
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
-
-
-
-
-
-
-
VERTEX presents data on cystic fibrosis drugs at conference
-
-
-
-
-
-
-
Vertex Announces Key Advancements Across Kidney Portfolio
-
333,574 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


